MediWound is a long-term buy opportunity with significant upside potential, driven by its innovative wound and lesion care products in a strong, growing industry. Despite current financial struggles, including increased losses and low margins, MediWound's revenue is expected to grow, and it garners support from government and industry investments. MDWD has shown strong momentum, nearly doubling...
Approval Helps Solidify NexoBrid's Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages Approval Helps Solidify NexoBrid's Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages
Completed Construction of New NexoBrid ® Manufacturing Facility €16.25 Million EIC Funding Expedites EscharEx ® Development for Diabetic Foot Ulcer s , Significantly Expanding the Addressable Market ; Phase III Study for Venous Leg Ulcers to Begin in H2 2024 $25 Million Strategic Investment Led by Mölnlycke Health Care Conference C all T oday, August 14 at 8:30am Eastern Time YAVNE, Israel, Aug...
NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients
Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time
Research Published in THE LANCET's eClinicalMedicine EscharEx ® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.